Lori Lyons-Williams is the president and chief operating officer of Neumora. She is an experienced executive and proven operational leader with a strong track record of strategic and commercial success across biotech and pharmaceutical companies. In addition to full P&L responsibility in competitive markets, she has authored strategy and guided teams through both R&D pipeline advancement and business development deals.
Before joining Neumora, Lori was chief commercial officer of Dermira, where she had responsibility for strategic, financial and operational leadership of the company’s portfolio. There, she helped lead the company’s transaction with Roche-Genentech to acquire worldwide rights to lebrikizumab, as well the company’s acquisition by Eli Lilly in 2020, valued at $1.1 billion. Previously, as the vice president of sales and marketing at Allergan, Lori built what became one of the company’s fastest growing business units in urology and led three major launches for ACZONE® in acne, BOTOX® in neurogenic detrusor overactivity and BOTOX® in overactive bladder. At Allergan, she also founded Women in Leadership to advocate for gender equity in the workplace.
Lori currently serves as an independent director on the board of Pipeline Therapeutics and previously served as independent director on the board of Five Prime Therapeutics.
Lori holds an MBA from the Carlson School of Management at the University of Minnesota and a B.A. from Virginia Tech.